ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NVO Novo Nordisk

89.79
4.79 (5.64%)
Pre Market
Last Updated: 10:11:26
Delayed by 15 minutes
Share Name Share Symbol Market Type
Novo Nordisk NYSE:NVO NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  4.79 5.64% 89.79 451,353 10:11:26

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

19/11/2024 2:24pm

Edgar (US Regulatory)


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

________________

 

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

November 19, 2024

________________

 

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

 

 

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

 

Form 20-F ☒           Form 40-F ☐

  

 
 

 

 

 

 

Trading in Novo Nordisk shares by board members, executives and associated persons

 

Bagsværd, Denmark, 19 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

 

The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

 

Please find below a statement of such trading in shares issued by Novo Nordisk.

 

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person David Moore
2 Reason for the notification
a) Position/status Executive Vice President, head of Corporate Development
b) Initial notification/Amendment Initial notification
3 Details of the issuer
a) Name Novo Nordisk A/S
b) LEI 549300DAQ1CVT6CXN342
4 Details of the transaction(s)

 

 

Page 2 of 3

 

a)

Description of the financial instrument,

type of instrument,

 

ADRs  
Identification code NVO  
b) Nature of the transaction Purchase of ADRs
c) Price(s) and volume(s)  
      Price(s) Volume(s)  
      DKK 709.25 2,500 ADRs  
           
           

d)

Aggregated information

·        Aggregated volume

·        Price

 

2,500 ADRs

DKK 1,773,118.70

e) Date of the transaction 2024-11-18
f) Place of the transaction New York Stock Exchange

 

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

 

Contacts for further information

 

Media:  

Ambre James-Brown

+45 3079 9289

abmo@novonordisk.com

Liz Skrbkova (US)

+1 609 917 0632

lzsk@novonordisk.com

   
Investors:  

Jacob Martin Wiborg Rode

+45 3075 5956

jrde@novonordisk.com

David Heiberg Landsted

+45 3077 6915

dhel@novonordisk.com

 

 

 

Page 3 of 3

 

Sina Meyer

+45 3079 6656

azey@novonordisk.com

Ida Schaap Melvold

+45 3077 5649

idmg@novonordisk.com

   

Frederik Taylor Pitter

+1 609 613 0568

fptr@novonordisk.com

 

 

 

 

 

 

 

 

 

 

Novo Nordisk A/S

Investor Relations

Novo Allé 1

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

www.novonordisk.com
CVR no: 24 25 67 90

   Company announcement No 90 / 2024

 

 
 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

 

Date: November 19, 2024

 

NOVO NORDISK A/S

 

Lars Fruergaard Jørgensen

Chief Executive Officer

 

 

 

 

 

 

 

 

 

 


1 Year Novo Nordisk Chart

1 Year Novo Nordisk Chart

1 Month Novo Nordisk Chart

1 Month Novo Nordisk Chart

Your Recent History

Delayed Upgrade Clock